immunoprobe
mapatumumab
drozitumab
lexatumumab
tisotumab
acrixolimab
heterophile
fontolizumab
agonistic monoclonal antibody
intrabody
pamrevlumab
tucotuzumab
elotuzumab
sonepcizumab
-toxa-
Ab
bivatuzumab
caplacizumab
tabalumab
matuzumab
lintuzumab
samalizumab
antipolyvalent
onartuzumab
intetumumab
antiantibody
glembatumumab
immunopanning
carlumab
immunocharacterize
evolocumab
nofetumomab
amlitelimab
ozoralizumab
polyclonal
adecatumumab
reagin
cixutumumab
antiustekinumab
zanolimumab
ramucirumab
ozogamicin
cibisatamab
antisubstance
presentation
antisynthetase
antiphospholipid
antigenomic
volociximab
autocentromere